Mr. Dean Burns reports

OCUMETICS ACHIEVES CLINICAL MILESTONES; POISED FOR VALUE-DEFINING FIRST-IN-HUMAN LENS IMPLANTATIONS

Ocumetics Technology Corp. has successfully completed key clinical milestones and has shared an update on the anticipated first-in-human (FIH) surgeries.

"This is a moment our entire team has been working toward for years," said Dean Burns, chief executive officer of Ocumetics. "Every milestone we've achieved in recent weeks reflects the dedication, expertise and sheer determination of our people and partners. We're now just a few days away from transforming the future of vision correction with the first implantation of our groundbreaking accommodating intraocular lens. I couldn't be prouder of what our team has accomplished."

Over the past several weeks, Ocumetics has made significant clinical progress:

• June 26, 2025 -- virtual site initiation of the clinical partner site in Mexico City completed, confirming readiness to conduct the FIH clinical study;
• July 9, 2025 -- completion of clinical study protocol training for the clinical team in Mexico City;
• July 30, 2025 -- receipt of verbal ethics committee approval for the study protocol, validating the site's compliance with the highest international standards for patient safety, scientific integrity and ethical principles;
• Aug. 5, 2025 -- commencement of patient recruitment at the Mexico City clinical site;
• Aug. 8, 2025 -- implantation of control lenses completed.

Upcoming clinical activities include:

• Final site initiation and surgeon training immediately prior to the FIH lens implantations;
• First-in-human implantation of the Ocumetics accommodating intraocular lens;
• Daily, weekly and monthly patient progress monitoring;
• Planning for group 2 surgeries, anticipated in Q1 2026.

Given the imminent FIH surgeries, the company has elected not to proceed with the second tranche of the private placement announced on June 4, 2025. Ocumetics successfully completed tranche 1 of the financing, raising $1,124,362 through the issuance of 3,212,462 units. The company paid fees of $68,610 and issued 196,029 agent's warrants to Numus Capital Corp. for its assistance on the financing. The company intends to introduce a financing with revised terms following the completion of these historic procedures.

About Ocumetics Technology Corp.

Ocumetics Technology is a Canadian research and product development company that is dedicated to developing advanced vision correction solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies.

Ocumetics is in the preclinical study phase of a game-changing technology for the ophthalmic industry. Ocumetics has developed an intraocular lens that fits within the natural lens compartment of the eye, potentially to eliminate the need for corrective lenses. It is designed to allow the eye's natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses.

We seek Safe Harbor.